Skip to content

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01270087
Enrollment
14
Registered
2011-01-05
Start date
2005-05-31
Completion date
2007-02-28
Last updated
2011-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid arthritis, cardiovascular disease, adalimumab

Brief summary

The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.

Interventions

DRUGAdalimumab

40 mg IV every 14 days

Sponsors

Abbott
CollaboratorINDUSTRY
The Swedish Research Council
CollaboratorOTHER_GOV
The Swedish Rheumatism Ass
CollaboratorOTHER
Crafoord Foundation
CollaboratorOTHER
Skane University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of rheumatoid arthritis * Fulfillment of the American College of Rheumatology 1987 criteria for rheumatoid arthritis * Active disease despite treatment with at least one disease modifying anti-rheumatic drug * Treatment with adalimumab indicated according to the the patient's rheumatologist * At least six swollen joints in 28-joint index * CRP \> 8 mg / L within the last three months

Exclusion criteria

* Treatment with anti-TNF drugs in the last three months * Treatment with intravenous corticosteroids within fourteen days * Ongoing treatment with oral high-dose corticosteroids (equivalent to ≥ 20 mg of prednisolon daily) or completed such treatment less than fifteen days before inclusion * Severe bleeding disorder * Extensive or refractory leg ulcers * Severe peripheral vascular disease

Design outcomes

Primary

MeasureTime frameDescription
Endothelial expression of HLA-DQ in muscle biopsies3 monthsVascular tissue area stained for HLA-DQ by immunohistochemistry, quantified by computer assisted image analysis
Endothelial expression of interleukin-1 alpha in muscle biopsies3 monthsVascular tissue area stained for interleukin-1 alpha by immunohistochemistry, quantified by computer assisted image analysis
Carotid artery intima-media thickness3 monthsThickness of the intima and media of the common carotid artery, measured by ultrasound. Mean of two measures of the right and left common carotid artery.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026